Trends in survival of ALS from a population-based registry

医学 比例危险模型 生存分析 人口 内科学 危险系数 人口学 外科 儿科 置信区间 环境卫生 社会学
作者
Elisa Bianchi,Elisabetta Pupillo,Antonio De Feudis,Gabriele Enia,Eugenio Vitelli,Ettore Beghi
出处
期刊:Amyotrophic lateral sclerosis & frontotemporal degeneration [Informa]
卷期号:23 (5-6): 344-352 被引量:9
标识
DOI:10.1080/21678421.2021.2004167
摘要

Objective: To assess survival of ALS patients in general and in selected demographic and clinical subgroups comparing two periods (1998–2000 vs. 2008–2010). Methods: Newly diagnosed adults resident of Lombardy, Northern Italy from a population-based registry were included. Data were collected on age at diagnosis, sex, site of onset, diagnostic delay, and El-Escorial diagnostic category. Patients were followed until death or last observation. Survival was evaluated using Kaplan–Meier curves and Cox's proportional hazards models. Results: In 2008–2010 (267 patients), median survival was 2.4 years and 1-year, 2-year, 3-year and 5-year survival rates were 79%, 56%, 41% and 24%. Longer survival was associated with male sex, younger age, spinal onset, and longer diagnostic delay. Multivariable analysis confirmed higher death in 65–69yr (HR 2.8; 95% CI 1.4-5.6), 70–74yr (HR 3.2; 95% CI 1.6-6.3) and 75 + yr (HR 6.9; 95% CI 3.5-13.8) categories, compared to ≤49yr, in females (HR 1.4; 95% CI 1.02-1.8), compared to males, and in patients diagnosed after 6–12 months (HR 1.9; 95% CI 1.4-2.7), compared with longer diagnostic delay. In 1998–2000 (235 patients), median survival was 2.2 years. The 1-year, 2-year, 3-year and 5-year survival rates were 77%, 53%, 38% and 20%. When adjusting for demographic and clinical variables, the HR for death in 2008–2010 versus 1998–2000 was 0.80 (95% CI 0.66–0.98). A significant increase of survival in 2008–2010 was found only in patients aged 50–59yr and 70–74yr at diagnosis. Conclusions: Survival of ALS has increased over time in the last decades, especially in middle aged and elderly patients. The benefits of comprehensive care in selected age groups might explain our findings.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zeno123456完成签到,获得积分10
刚刚
陈某某发布了新的文献求助10
刚刚
1秒前
he完成签到,获得积分10
1秒前
1秒前
科研小民工应助忍冬半夏采纳,获得30
1秒前
小马甲应助年华采纳,获得10
1秒前
1秒前
CipherSage应助开放的听枫采纳,获得10
1秒前
Never stall发布了新的文献求助10
1秒前
1秒前
Jolene66发布了新的文献求助10
2秒前
zy完成签到,获得积分10
2秒前
Adzuki0812完成签到,获得积分10
2秒前
2秒前
2秒前
3秒前
3秒前
Anne应助哇哈哈采纳,获得10
4秒前
四季刻歌完成签到,获得积分10
4秒前
忆点儿孤狼完成签到,获得积分10
4秒前
搜集达人应助高贵的迎蕾采纳,获得10
4秒前
华仔应助一平采纳,获得10
5秒前
汉堡包应助bluer采纳,获得10
5秒前
5秒前
5秒前
直率心锁完成签到,获得积分10
5秒前
6秒前
李若水完成签到,获得积分10
6秒前
默默水之发布了新的文献求助10
6秒前
zink发布了新的文献求助10
7秒前
8秒前
映寒完成签到,获得积分10
8秒前
JamesPei应助幸福胡萝卜采纳,获得10
9秒前
9秒前
9秒前
Never stall完成签到,获得积分10
10秒前
鱼啦啦完成签到,获得积分10
10秒前
10秒前
猫了个喵完成签到,获得积分10
11秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Social media impact on athlete mental health: #RealityCheck 1020
Ensartinib (Ensacove) for Non-Small Cell Lung Cancer 1000
Unseen Mendieta: The Unpublished Works of Ana Mendieta 1000
Bacterial collagenases and their clinical applications 800
El viaje de una vida: Memorias de María Lecea 800
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3527469
求助须知:如何正确求助?哪些是违规求助? 3107497
关于积分的说明 9285892
捐赠科研通 2805298
什么是DOI,文献DOI怎么找? 1539865
邀请新用户注册赠送积分活动 716714
科研通“疑难数据库(出版商)”最低求助积分说明 709678